Cargando…
Nephrotoxicity in a Patient With Inadequate Pain Control: Potential Role of Pharmacogenetic Testing for Cytochrome P450 2D6 and Apolipoprotein L1
A case is presented which demonstrates the perils of opioid inefficacy and how pharmacogenomic testing may have prevented nonsteroidal anti-inflammatory drug (NSAID)-induced nephrotoxicity and progression to chronic kidney disease (CKD). A 62 year-old female with back pain was treated with tramadol...
Autores principales: | Tillman, Emma M., Skaar, Todd C., Eadon, Michael T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960206/ https://www.ncbi.nlm.nih.gov/pubmed/31969823 http://dx.doi.org/10.3389/fphar.2019.01511 |
Ejemplares similares
-
Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance
por: Zanger, Ulrich M., et al.
Publicado: (2013) -
Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children
por: Aka, Ida, et al.
Publicado: (2017) -
The role of pharmacogenetics of cytochrome P450s in phenytoin-induced DRESS syndrome
por: Yaşar, Ümit
Publicado: (2018) -
Whole Genome Amplification of DNA for Genotyping Pharmacogenetics Candidate Genes
por: Philips, Santosh, et al.
Publicado: (2012) -
Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes
por: Raunio, Hannu, et al.
Publicado: (2015)